

# Philip M Spanheimer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1746051/publications.pdf>

Version: 2024-02-01

33  
papers

614  
citations

687363

13  
h-index

610901

24  
g-index

34  
all docs

34  
docs citations

34  
times ranked

847  
citing authors

#	ARTICLE	IF	CITATIONS
1	International Medullary Thyroid Carcinoma Grading System: A Validated Grading System for Medullary Thyroid Carcinoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 96-104.	1.6	57
2	ASO Visual Abstract: Sociodemographic and Clinical Predictors of Neoadjuvant Chemotherapy in cT1-T2/NO HER2-Amplified Breast Cancer. <i>Annals of Surgical Oncology</i> , 2022, , 1.	1.5	0
3	Sociodemographic and Clinical Predictors of Neoadjuvant Chemotherapy in cT1-T2/NO HER2-Amplified Breast Cancer. <i>Annals of Surgical Oncology</i> , 2022, 29, 3051-3061.	1.5	3
4	Abstract P3-15-01: Patients and Researchers Together (PART); a patient-centered tumor tissue collection PARTnership between patients and researchers to increase tissue donations for breast cancer research. <i>Cancer Research</i> , 2022, 82, P3-15-01-P3-15-01.	0.9	0
5	The impact of age and nodal status on variations in oncotype DX testing and adjuvant treatment. <i>Npj Breast Cancer</i> , 2022, 8, 27.	5.2	7
6	Does Angiosarcoma of the Breast Need Nodal Staging?. <i>Journal of the American College of Surgeons</i> , 2022, 234, 774-782.	0.5	2
7	Pathologic complete response and survival after neoadjuvant chemotherapy in cT1-T2/NO HER2+ breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 65.	5.2	5
8	Prevalence of Pathologic N2/N3 Disease in Postmenopausal Women with Clinical NO ER+/HER2+ Breast Cancer. <i>Annals of Surgical Oncology</i> , 2022, 29, 7662-7669.	1.5	5
9	The Prognostic Value of Axillary Staging Following Neoadjuvant Chemotherapy in Inflammatory Breast Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 2182-2190.	1.5	9
10	Pathologic nodal staging for clinically node negative soft tissue sarcoma of the extremities. <i>Journal of Surgical Oncology</i> , 2021, 123, 1792-1800.	1.7	6
11	Prophylactic Lateral Neck Dissection for Medullary Thyroid Carcinoma is not Associated with Improved Survival. <i>Annals of Surgical Oncology</i> , 2021, 28, 6572-6579.	1.5	18
12	A Pilot Study of Preoperative Vandetanib on Markers of Proliferation and Apoptosis in Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 456-462.	1.3	6
13	Suboptimal therapy following breast conserving surgery in triple-negative and HER2-positive breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 509-520.	2.5	5
14	Bridging Endocrine Therapy for HR+/HER2- Resectable Breast Cancer: Is it Safe?. <i>American Surgeon</i> , 2021, , 000313482110472.	0.8	1
15	Dosimetric and Clinical Factors Associated With Breast Reconstruction Complications in Patients Receiving Postmastectomy Radiation. <i>Practical Radiation Oncology</i> , 2021, , .	2.1	1
16	Grading of medullary thyroid carcinoma on the basis of tumor necrosis and high mitotic rate is an independent predictor of poor outcome. <i>Modern Pathology</i> , 2020, 33, 1690-1701.	5.5	42
17	Long-Term Oncologic Outcomes After Curative Resection of Familial Medullary Thyroid Carcinoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 4423-4429.	1.5	6
18	ASO Author Reflections: Malignant/Borderline Phyllodes Tumors Without Uniformly Poor Histologic Features Have an Excellent Prognosis. <i>Annals of Surgical Oncology</i> , 2019, 26, 619-620.	1.5	1

#	ARTICLE	IF	CITATIONS
19	Long-Term Outcomes After Surgical Treatment of Malignant/Borderline Phyllodes Tumors of the Breast. <i>Annals of Surgical Oncology</i> , 2019, 26, 2136-2143.	1.5	30
20	Robotic proctectomy for rectal cancer: analysis of 71 patients from a single institution. <i>International Journal of Medical Robotics and Computer Assisted Surgery</i> , 2017, 13, e1841.	2.3	10
21	Incidence, characteristics, and management of recently diagnosed, microscopically invasive breast cancer by receptor status: Iowa SEER 2000 to 2013. <i>American Journal of Surgery</i> , 2017, 214, 323-328.	1.8	8
22	EGFR Is Regulated by TFAP2C in Luminal Breast Cancer and Is a Target for Vandetanib. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 503-511.	4.1	31
23	Receptor Tyrosine Kinase Expression Predicts Response to Sunitinib in Breast Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 4287-4294.	1.5	21
24	Inhibition of RET Increases the Efficacy of Antiestrogen and Is a Novel Treatment Strategy for Luminal Breast Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 2115-2125.	7.0	39
25	Sumoylation Pathway Is Required to Maintain the Basal Breast Cancer Subtype. <i>Cancer Cell</i> , 2014, 25, 748-761.	16.8	72
26	Distinct Pathways Regulated by RET and Estrogen Receptor in Luminal Breast Cancer Demonstrate the Biological Basis for Combination Therapy. <i>Annals of Surgery</i> , 2014, 259, 793-799.	4.2	27
27	The response to neoadjuvant chemotherapy predicts clinical outcome and increases breast conservation in advanced breast cancer. <i>American Journal of Surgery</i> , 2013, 206, 2-7.	1.8	45
28	Do giant parathyroid adenomas represent a distinct clinical entity?. <i>Surgery</i> , 2013, 154, 714-719.	1.9	48
29	High TFAP2C/low CD44 expression is associated with an increased rate of pathologic complete response following neoadjuvant chemotherapy in breast cancer. <i>Journal of Surgical Research</i> , 2013, 184, 519-525.	1.6	12
30	Expression of the RET Proto-oncogene Is Regulated by TFAP2C in Breast Cancer Independent of the Estrogen Receptor. <i>Annals of Surgical Oncology</i> , 2013, 20, 2204-2212.	1.5	24
31	Reply to Comment on "Surveillance and Intervention after Thyroid Lobectomy". <i>Annals of Surgical Oncology</i> , 2011, 18, 309-309.	1.5	1
32	Measurement of Uterine Radiation Exposure from Lymphoscintigraphy Indicates Safety of Sentinel Lymph Node Biopsy during Pregnancy. <i>Annals of Surgical Oncology</i> , 2009, 16, 1143-1147.	1.5	72
33	ASO Author Reflections: Can Genomic Recurrence Score Replace SLNB in Postmenopausal Women with ER+/HER2 <sup>-</sup> Breast Cancer?. <i>Annals of Surgical Oncology</i> , 0, , .	1.5	0